-
From Our LabsTurning up the heat on tumors
From Our Labs -
From Our LabsVision hacker
Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.
From Our Labs -
DiscoveryLet there be sight
Discovery -
Patient PerspectivesWhy research into rare diseases matters
Hundreds of millions of people worldwide await treatments for rare diseases.
Patient Perspectives -
From Our LabsChemical genetics: The sleuthing behind modern drug discovery
Researchers at Novartis are combining modern techniques with an old approach to drug discovery and getting surprising results.
From Our Labs -
DiscoveryResearchers aim to beat trick play by tumors with drug combo
Discovery -
From Our LabsCan we edit our genes to fight disease?
From Our Labs -
From Our LabsRebuilding blood
Why are some sickle cell disease patients protected from the disease? Learn about our biomedical research in the field.
From Our Labs -
Access to HealthcareTalking to: Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility at Novartis
In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.
Access to Healthcare -
DiscoveryA fresh look at fighting glaucoma
Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.
Discovery -
DiscoveryCan we unlock the body's ability to regenerate lost hearing?
When a middle-aged firefighter and active Boy Scout leader in the Midwestern United States lost his hearing a few years ago, he also faced the loss of his livelihood.
Discovery -
Access to HealthcareTreating cataracts, a leading cause of preventable blindness worldwide
Cataracts are a serious but common eye condition affecting more than 20 million worldwide. A patient in Brazil tells her story.
Access to Healthcare